Veraxa Biotech is trading 10.22% lower at $1.13; the reason for the decline remains unclear. - Its latest listed release, dated October 7, discussed FDA-aligned research methods. - The World ADC Congress began October 12, but neither it nor the release is reported as causing the drop. - Major indices were moving only modestly, and the supplied context does not establish a broad-market explanation.